Rheopheresis
Jump to navigation
Jump to search
Rheopheresis is a process to change the viscosity of blood by filtering blood to remove some components such as fibrinogen, alpha-2-macroglobulin, von Willebrand factor, LDL cholesterol and immunoglobulin M.[1]
It is an experimental treatment for dry age-related macular degeneration,[2] and acute ischemic stroke.[3]
References
- ^ Klingel, Reinhard; Fassbender, Cordula; Fassbender, Thurid; Erdtracht, Bernard; Berrouschot, Jörg (1 October 2000). "Rheopheresis: rheologic, functional, and structural aspects". Therapeutic Apheresis. 4 (5): 348–357. doi:10.1046/j.1526-0968.2000.004005348.x. PMID 11111816.
- ^ Leung, E; Landa, G (September 2013). "Update on current and future novel therapies for dry age-related macular degeneration". Expert Review of Clinical Pharmacology. 6 (5): 565–79. doi:10.1586/17512433.2013.829645. PMID 23971874. S2CID 26680094.
- ^ Berrouschot, J; Barthel, H; Köster, J; Hesse, S; Rössler, A; Knapp, WH; Schneider, D (April 1999). "Extracorporeal rheopheresis in the treatment of acute ischemic stroke: A randomized pilot study". Stroke. 30 (4): 787–92. doi:10.1161/01.STR.30.4.787. PMID 10187880.
 | This medical treatment–related article is a stub. You can help Wikipedia by expanding it. |